AstraZeneca has recently launched a new global health tech business, Evinova, with the goal of revolutionizing the clinical trial process. The company aims to reduce the time and cost of clinical trials while making the process easier for patients. Evinova was created to fill a gap in the market for these services and will operate as a separate business, financially backed by AstraZeneca.

Evinova will provide global services to CROs and pharmaceutical companies, allowing them to design, run, and monitor clinical trials more efficiently. The company will charge customers for access to its technology and operate on a revenue-based model. By creating Evinova, AstraZeneca hopes to address the challenges and inefficiencies in the clinical trial process, ultimately making it easier for patients to participate and improving the overall effectiveness of the trials.

This new venture reflects AstraZeneca’s commitment to advancing healthcare through technology. With Evinova’s cutting-edge technology and expertise in clinical trials, AstraZeneca is poised to transform the drug development process and bring new treatments to market faster than ever before.

By Editor

Leave a Reply